The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma.
epithelial mesenchymal transition
malignant pleural mesothelioma
miRNAs
oxidative stress
transforming growth factor β
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Nov 2021
11 Nov 2021
Historique:
received:
23
09
2021
revised:
27
10
2021
accepted:
03
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
16
12
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive tumor mainly associated with asbestos exposure and is characterized by a very difficult pharmacological approach. One of the molecular mechanisms associated with cancer onset and invasiveness is the epithelial-to-mesenchymal transition (EMT), an event induced by different types of inducers, such as transforming growth factor β (TGFβ), the main inducer of EMT, and oxidative stress. MPM development and metastasis have been correlated to EMT; On one hand, EMT mediates the effects exerted by asbestos fibers in the mesothelium, particularly via increased oxidative stress and TGFβ levels evoked by asbestos exposure, thus promoting a malignant phenotype, and on the other hand, MPM acquires invasiveness via the EMT event, as shown by an upregulation of mesenchymal markers or, although indirectly, some miRNAs or non-coding RNAs, all demonstrated to be involved in cancer onset and metastasis. This review aims to better describe how EMT is involved in driving the development and invasiveness of MPM, in an attempt to open new scenarios that are useful in the identification of predictive markers and to improve the pharmacological approach against this aggressive cancer.
Identifiants
pubmed: 34830097
pii: ijms222212216
doi: 10.3390/ijms222212216
pmc: PMC8621591
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Neoplasm Proteins
0
RNA, Neoplasm
0
Transforming Growth Factor beta
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Int J Mol Sci. 2018 Apr 26;19(5):
pubmed: 29701689
Exp Cell Res. 2015 Mar 1;332(1):102-15
pubmed: 25557874
Mol Cell Biochem. 2010 Jul;340(1-2):195-202
pubmed: 20204677
Mol Med Rep. 2014 Aug;10(2):1089-95
pubmed: 24890460
Cancer Biol Ther. 2005 Mar;4(3):342-6
pubmed: 15846066
Int Immunopharmacol. 2002 Feb;2(2-3):191-200
pubmed: 11811924
Oncol Rep. 2014 Jun;31(6):2660-8
pubmed: 24715097
Cancer Cell. 2013 Oct 14;24(4):466-80
pubmed: 24075834
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Am J Pathol. 2013 Nov;183(5):1654-66
pubmed: 24160326
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Dev Cell. 2021 Mar 22;56(6):726-746
pubmed: 33756119
Cancer Sci. 2020 Jun;111(6):2016-2027
pubmed: 32248600
Int J Mol Sci. 2018 Jun 28;19(7):
pubmed: 29958433
BMC Cancer. 2018 Aug 15;18(1):819
pubmed: 30111297
Cytokine. 2021 Oct;146:155622
pubmed: 34153874
Med Oncol. 2014 Dec;31(12):303
pubmed: 25358615
APMIS. 2013 Jan;121(1):1-10
pubmed: 23030626
Oncotarget. 2017 Jun 2;8(35):59500-59508
pubmed: 28938653
Cell Motil Cytoskeleton. 2006 Oct;63(10):646-57
pubmed: 16937396
Front Immunol. 2017 Sep 13;8:1106
pubmed: 28955335
Antioxid Redox Signal. 2012 Jun 1;16(11):1248-63
pubmed: 21929373
J Proteome Res. 2014 Jun 6;13(6):2874-86
pubmed: 24766643
J Thorac Dis. 2018 Jan;10(Suppl 2):S293-S297
pubmed: 29507798
Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72
pubmed: 19781955
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
Oncology. 2014;86(2):109-16
pubmed: 24457449
Cancers (Basel). 2020 May 19;12(5):
pubmed: 32438640
Cancer Res. 1987 Dec 1;47(23):6180-4
pubmed: 3479241
Cancer Res. 2001 Jun 15;61(12):4766-72
pubmed: 11406550
Arch Environ Occup Health. 2020;75(8):471-482
pubmed: 32308151
Cancer Lett. 2011 Mar 28;302(2):136-43
pubmed: 21300430
J Exp Med. 2012 Mar 12;209(3):479-94
pubmed: 22329991
Mod Pathol. 2010 Mar;23(3):470-9
pubmed: 20081811
Lung Cancer. 2021 Jul;157:48-59
pubmed: 33972125
Sci Rep. 2016 Jun 23;6:28587
pubmed: 27335258
Int J Mol Sci. 2019 Jan 03;20(1):
pubmed: 30609805
J Thorac Dis. 2015 Jun;7(6):1031-40
pubmed: 26150916
Elife. 2018 Jan 29;7:
pubmed: 29376829
Am J Respir Cell Mol Biol. 1997 Nov;17(5):599-607
pubmed: 9374111
Sci Rep. 2018 Jul 3;8(1):10070
pubmed: 29968778
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Semin Cancer Biol. 2019 Oct;58:1-10
pubmed: 30453041
EMBO Rep. 2008 Jun;9(6):582-9
pubmed: 18483486
Asian Pac J Cancer Prev. 2013;14(6):3625-30
pubmed: 23886156
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Virchows Arch. 2021 Jan;478(1):59-72
pubmed: 33475835
Oncotarget. 2017 Aug 24;8(44):78193-78207
pubmed: 29100460
Carcinogenesis. 2018 Apr 5;39(4):534-545
pubmed: 29635378
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23
pubmed: 19838011
Mol Oncol. 2020 Jun;14(6):1207-1223
pubmed: 32083805
Am J Respir Cell Mol Biol. 1995 May;12(5):455-60
pubmed: 7742009
J Cell Biochem. 2012 Jul;113(7):2234-47
pubmed: 22573546
Oncotarget. 2017 Apr 4;8(14):22625-22639
pubmed: 28186986
Anticancer Res. 2007 Jan-Feb;27(1A):39-44
pubmed: 17352214
Int J Mol Sci. 2018 Nov 20;19(11):
pubmed: 30463358
Mol Cancer Res. 2021 Sep 30;:
pubmed: 34593606
Arch Pathol Lab Med. 2018 Jun;142(6):753-760
pubmed: 29480760
Front Oncol. 2021 Jun 23;11:660039
pubmed: 34249695
Inhal Toxicol. 2017 Oct - Dec;29(12-14):541-554
pubmed: 29458304
Thorac Cancer. 2021 Feb;12(4):491-503
pubmed: 33319489
J Toxicol Environ Health B Crit Rev. 2011;14(1-4):153-78
pubmed: 21534088
Front Oncol. 2021 May 20;11:668731
pubmed: 34094963
Arch Pharm Res. 2019 Oct;42(10):890-901
pubmed: 31428976
J Cell Mol Med. 2016 Sep;20(9):1761-9
pubmed: 27027258
Int J Biol Sci. 2016 Oct 18;12(11):1279-1288
pubmed: 28090191
Trends Cancer. 2020 Nov;6(11):942-950
pubmed: 32680650
Oncotarget. 2018 Oct 2;9(77):34495-34505
pubmed: 30349644
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21677-82
pubmed: 21098274
Front Oncol. 2020 Feb 07;10:105
pubmed: 32117755
Lab Invest. 2004 Aug;84(8):1013-23
pubmed: 15122306
Environ Health Perspect. 2016 Jun;124(6):776-84
pubmed: 26685284
Lung Cancer. 2020 Jan;139:124-132
pubmed: 31778960
Arch Pharm Res. 2019 Jan;42(1):14-24
pubmed: 30649699
Antioxid Redox Signal. 2010 Jun 15;12(12):1383-430
pubmed: 19903090
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Oncotarget. 2017 Oct 6;8(58):98280-98297
pubmed: 29228689
Cancers (Basel). 2020 Apr 10;12(4):
pubmed: 32290283
Oxid Med Cell Longev. 2015;2015:654594
pubmed: 26078812
Transl Lung Cancer Res. 2021 Jun;10(6):2988-3000
pubmed: 34295692
Clin Cancer Res. 2021 Sep 1;27(17):4669-4679
pubmed: 33827891
Front Oncol. 2020 Feb 18;10:126
pubmed: 32133285
Transl Res. 2009 Apr;153(4):143-52
pubmed: 19304273
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S39-S46
pubmed: 32206569
Cells. 2020 Mar 02;9(3):
pubmed: 32121660
Pathology. 2016 Dec;48(7):650-659
pubmed: 27956272